Aigen Investment Management LP decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 55.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,275 shares of the biotechnology company's stock after selling 4,106 shares during the period. Aigen Investment Management LP's holdings in Repligen were worth $487,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the business. Toronto Dominion Bank lifted its stake in Repligen by 1.5% in the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock worth $656,000 after purchasing an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in shares of Repligen by 1.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock valued at $982,000 after purchasing an additional 89 shares during the period. Ballentine Partners LLC boosted its holdings in shares of Repligen by 6.2% during the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock valued at $269,000 after buying an additional 105 shares in the last quarter. Diversified Trust Co increased its stake in shares of Repligen by 3.7% in the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock worth $372,000 after acquiring an additional 106 shares in the last quarter. Finally, CWM LLC lifted its position in Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 114 shares during the period. Institutional investors own 97.64% of the company's stock.
Repligen Stock Performance
Shares of Repligen stock traded down $17.70 during trading hours on Friday, reaching $124.73. 1,915,115 shares of the stock traded hands, compared to its average volume of 665,967. Repligen Co. has a one year low of $113.50 and a one year high of $211.13. The firm has a market capitalization of $6.99 billion, a price-to-earnings ratio of -337.10, a P/E/G ratio of 4.36 and a beta of 0.96. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The company has a 50 day moving average price of $141.54 and a 200 day moving average price of $144.77.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the business posted $0.23 earnings per share. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. On average, equities research analysts expect that Repligen Co. will post 1.44 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research firms recently weighed in on RGEN. UBS Group reduced their price objective on Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, July 31st. Wells Fargo & Company assumed coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price objective for the company. Stephens reiterated an "overweight" rating and set a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. Benchmark reaffirmed a "hold" rating on shares of Repligen in a research report on Monday, August 5th. Finally, StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Repligen presently has an average rating of "Moderate Buy" and a consensus target price of $190.25.
View Our Latest Analysis on RGEN
Insider Buying and Selling
In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by insiders.
Repligen Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
